Residual Scope: A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients

Medicine and Dentistry

1. Child 100%
2. Lymphoid Leukemia 100%
3. Patient 100%
4. Therapeutic Procedure 100%
5. Down Syndrome 100%
6. Blinatumomab 100%
7. Chemotherapy 100%
8. Disease Free Survival 33%
9. Risk Stratification 33%
10. Lymphoblastic Lymphoma 33%
11. Flow Cytometry 33%
12. Long Term Survival 33%
13. Neoplasm 33%
14. Overall Survival 33%
15. DNA 33%
16. Immunoglobulin Heavy Chain 33%